Medication evidence profile
Lofepramine
Clinical overview
Lofepramine has a public medication-list entry in JARS 2025. This profile has one source version to examine, so a cross-scale comparison is not available from these rows.
Source-specific scores
| Source | Score |
|---|---|
| JARS | 2 |
| Yamada-ABS | Not listed |
| BAAS | Not listed |
| Swe-ABS | Not listed |
| GABS | Not listed |
| KABS | Not listed |
| CALS | Not listed |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
How to interpret the evidence
1 of 7 public source versions contain an explicit medication-list entry for Lofepramine.
None of the public rows in this profile is an explicit zero. An unlisted source still supplies no value.
Source labels and provenance · 1 observation
- Japanese Anticholinergic Risk Scale (JARS) 2025 English translation
Source label: Lofepramine. Published value: 2.
Source version: JARS-2025
Source location: RC4 source recovery; recovery_scope=primary_table_complete; ATC=N06AA07
Observation: JARS_2025_R0054; rating state: published_rating.
Dose, route, and formulation notes
Distinct v3 concept retained conservatively; do not collapse by substring or class similarity.
What this page does not establish
- No medication-list entry is available here from Yamada-ABS 2023, BAAS 2019, Swe-ABS 2023, GABS 2018, KABS 2020 open validation supplement, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- Use source-specific route/formulation where provided.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Mizokami F, Mizuno T, Taguchi R, et al. Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 2025;25(1):5-13. doi:10.1111/ggi.15001. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Lofepramine
Ask about this medication